ADPT president sells shares after option exercises
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Adaptive Biotechnologies President and COO Julie Rubinstein reported a series of option exercises and share sales in Adaptive Biotechnologies Corp. Between April 14 and April 16, 2026, she exercised stock options to acquire a total of 44,166 shares of common stock at an exercise price of $8.46 per share.
Over the same period, she sold 57,180 shares of common stock in open-market transactions, including sales reported at weighted average prices of $14.18, $14.61 and $14.56 per share. These transactions were carried out under a Rule 10b5-1 trading plan adopted on November 18, 2025. Following the transactions, she directly holds 408,160 shares of Adaptive Biotechnologies common stock.
Insider Trade Summary 10b5-1
Exercise and sale activity reported; no spread calculated
Exercise and Sale
9 txns
Insider
RUBINSTEIN JULIE
Role
President and COO
Sold
57,180 shs ($826K)
Approx. gross sale proceeds
$826K
Approx. exercise cost
$374K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) | 14,722 | $0.00 | $0.00 |
| Exercise | Common Stock | 14,722 | $8.46 | $125K |
| Sale | Common Stock | 19,060 | $14.18 | $270K |
| Exercise | Stock Option (right to buy) | 14,722 | $0.00 | $0.00 |
| Exercise | Common Stock | 14,722 | $8.46 | $125K |
| Sale | Common Stock | 19,060 | $14.61 | $278K |
| Exercise | Stock Option (right to buy) | 14,722 | $0.00 | $0.00 |
| Exercise | Common Stock | 14,722 | $8.46 | $125K |
| Sale | Common Stock | 19,060 | $14.56 | $278K |
Holdings After Transaction:
Stock Option (right to buy) — 148,770 contracts (Direct);
Common Stock — 408,160 shares (Direct)
Footnotes (5)
- F1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
- F2. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.17 to $14.80, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- F3. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.49 to $14.81, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- F4. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.01 to $14.31, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- F5. The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
Key Figures
Options exercised: 44,166 shares
Exercise price: $8.46 per share
Shares sold: 57,180 shares
+5 more
8 metrics
Options exercised
44,166 shares
Total common shares acquired via option exercises on April 14–16, 2026
Exercise price
$8.46 per share
Strike price for stock options exercised into common stock
Shares sold
57,180 shares
Total common shares sold in open-market transactions over three days
Sale price (April 16)
$14.18 per share
Weighted average price for 19,060 shares sold on April 16, 2026
Sale price (April 15)
$14.61 per share
Weighted average price for 19,060 shares sold on April 15, 2026
Sale price (April 14)
$14.56 per share
Weighted average price for 19,060 shares sold on April 14, 2026
Post-transaction holdings
408,160 shares
Directly owned Adaptive Biotechnologies common shares after all transactions
Rule 10b5-1 plan adoption
November 18, 2025
Date the pre-arranged trading plan governing these transactions was adopted
Key Terms
Rule 10b5-1 trading plan, Stock Option (right to buy, weighted average price, open-market sale, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Stock Option (right to buy financial
"security_title": "Stock Option (right to buy)"
weighted average price financial
"The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
open-market sale financial
"transaction_action": "open-market sale"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Adaptive Biotechnologies (ADPT) executive Julie Rubinstein report in this Form 4?
Julie Rubinstein, President and COO of Adaptive Biotechnologies, reported option exercises and share sales. She exercised options for 44,166 shares at $8.46 and sold 57,180 shares in open-market trades, while remaining directly invested with 408,160 shares after the transactions.
What stock options did Julie Rubinstein exercise at Adaptive Biotechnologies (ADPT)?
She exercised stock options covering 44,166 shares of Adaptive Biotechnologies common stock. These options had an exercise price of $8.46 per share and were exercised in three tranches on April 14, 15 and 16, 2026, according to the Form 4 transaction details.
Were Julie Rubinstein’s Adaptive Biotechnologies (ADPT) trades made under a Rule 10b5-1 plan?
Yes. A footnote states the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on November 18, 2025. Such plans pre-schedule trades, indicating these sales followed a pre-arranged program rather than discretionary, ad hoc timing decisions.
AI-generated analysis. How Rhea-AI works. Not financial advice.
